Serina Therapeutics presenting new drug candidate SER-252 for Parkinson's symptoms relief

From GlobeNewswire: 2025-06-23 19:24:00

Serina Therapeutics is hosting a live webinar on June 26, 2025, to discuss their new drug candidate, SER-252, designed to provide continuous relief for Parkinson’s symptoms. The drug utilizes a proprietary technology, POZ Platform™, to deliver continuous dopaminergic stimulation for smoother symptom control. The CEO, Steve Ledger, will explore the limitations of current treatments and the potential benefits of this next-gen approach. Interested individuals can register for the event on the FORCE Family Office website. Serina Therapeutics is a biotech company focused on developing innovative treatments for neurological diseases, headquartered in Huntsville, Alabama.



Read more at GlobeNewswire: Serina Therapeutics to Present at FORCE Family Office